Most people, if they’re being honest, don’t have a clear plan for what they’ll be doing in their careers five years from now.
But career planning is serious, high-stakes business for biotech venture capitalists. When a firm raises a new fund to invest in biotechnology, the partners have to personally commit to oversee their investments for 10 to 12 years. While most people get an annual performance review from their boss, biotech VCs generally have to wait a decade to get a true read on their performance.
To read the full, original article click on this link: Who Will Survive the Biotech VC Downturn? The Young and the Proven | Xconomy
